Systemic biomarkers of allogeneic haematopoietic stem cell transplantation outcome-Brief introduction

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F19%3AN0000191" target="_blank" >RIV/00098892:_____/19:N0000191 - isvavai.cz</a>

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1111/tan.13761" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1111/tan.13761</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/tan.13761" target="_blank" >10.1111/tan.13761</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Systemic biomarkers of allogeneic haematopoietic stem cell transplantation outcome-Brief introduction

Popis výsledku v původním jazyce

Although complex approaches in haematopoietic stem cell transplantation (aHSCT) improved substantially in the last decades, considerable proportion of patients still suffer from life-threatening complications including graft versus host disease (GvHD). Great effort has therefore been dedicated to identification of biomarkers of the aHSCT outcome. Recently, prognostic scores for the prediction of GvHD and non-relapse mortality based on circulating molecules, such as tumour necrosis factor receptor-1, IL-33receptor (ST2) and regenerating islet-derived 3-alpha were proposed and evaluated in multicentre studies. Furthermore, several biomarkers, for example, ST2, represent promising targets for therapeutic intervention in severe GvHD. These results bring us closer to the clinical strategies to effectively control complications following aHSCT, and therefore to the tailored stem cell therapy with higher benefits for the patients.

Název v anglickém jazyce

Systemic biomarkers of allogeneic haematopoietic stem cell transplantation outcome-Brief introduction

Popis výsledku anglicky

Although complex approaches in haematopoietic stem cell transplantation (aHSCT) improved substantially in the last decades, considerable proportion of patients still suffer from life-threatening complications including graft versus host disease (GvHD). Great effort has therefore been dedicated to identification of biomarkers of the aHSCT outcome. Recently, prognostic scores for the prediction of GvHD and non-relapse mortality based on circulating molecules, such as tumour necrosis factor receptor-1, IL-33receptor (ST2) and regenerating islet-derived 3-alpha were proposed and evaluated in multicentre studies. Furthermore, several biomarkers, for example, ST2, represent promising targets for therapeutic intervention in severe GvHD. These results bring us closer to the clinical strategies to effectively control complications following aHSCT, and therefore to the tailored stem cell therapy with higher benefits for the patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

HLA

ISSN

2059-2302

e-ISSN

2059-2310

Svazek periodika

94

Číslo periodika v rámci svazku

Suppl. S2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

25-29

Kód UT WoS článku

000521282900006

EID výsledku v databázi Scopus

2-s2.0-85076887994